An open-label, single-center, phase II study of exploration on optimizing the administration time of fruquintinib combined with camrelizumab in the third-line treatment of MSS advanced colorectal cancer
Latest Information Update: 03 Mar 2022
At a glance
- Drugs Camrelizumab (Primary) ; Fruquintinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 03 Mar 2022 New trial record
- 22 Jan 2022 As of September 23, 2021, a total of 21 patients have been enrolled
- 22 Jan 2022 Trial design presented at the 2022 Gastrointestinal Cancers Symposium